All In Biotech

Drug Trial Radar · NCT05718856

TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)

A Multicenter, Randomized, Open-label StudyTo Compare The Efficacy And Safety Of TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in Persistent or Chronic Pediatric ITP Patients Who Failed or Relapse After Glucocorticoid Therapy

Last checked: Nov 19, 2026Latest source record: Jul 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 166 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

166

Planned (sponsor's estimate)

Start

Feb 23, 2023

Primary completion

May 14, 2025

Study completion Nov 14, 2025

Sponsor

Lead sponsor
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Beijing Children's Hospital; Tianjin People's Hospital; The Second Affiliated Hospital of Kunming Medical University; Henan Cancer Hospital; Tianjin Medical University Second Hospital; The First Affiliated Hospital of Xiamen University
First posted
Feb 8, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 6 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This multicenter randomized, open-label study aim to compare the efficacy and safety of TPO-RAs combining anti-CD 20 monoclonal antibody with TPO-RAs in China pediatric ITP patients .This study will be conducted in persistent or chronic pediatric ITP patients who had not responded to or had relapsed after previous glucocorticoid treatment.

Conditions

  • Primary Immune Thrombocytopenia (ITP)

Interventions

  • TPO-RAsDrug

    After enrollment, all subjects receive TPO-RAs treatment. The initial dose of eltrombopag, hetrombopag and avatrombopag administration were the same as described in arm description. Complete blood count including platelet count was done once a week. The dose of TPO-RAs was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count \>250×10\^9/L, the TPO-RAs will stop until the platelet count \<100×10\^9/L.

  • TPO-RAs combining anti-CD 20 monoclonal antibodyDrug

    After enrollment, all subjects receive TPO-RAs treatment. The initial dose of eltrombopag, hetrombopag and avatrombopag administration were the same as described in arm description.The dose of TPO-RAs was adjusted according to the subject platelet count during the period from week 1 to week 24. Subjects in TPO-RAs combining anti-CD 20 monoclonal antibody treatment group received single dose infusion of Rituximab 375 mg/m2 within 14 days after enrollment. Subjects weighing less than 30kg will be given Rituximab 100 mg once a week for four times. Ortuzumab at 1000mg/ dose is also recommended for subjects weighing 45kg or greater. Ps.Participants in the TPO-RAs monotherapy group who have platelet count \< 20×10\^9/L or significant skin and mucosal bleeding at the end of 12 weeks of treatment will be given a single dose of Rituximab 375mg/m2 or Ortuzumab at 1000mg/ dose if weighing 45kg or greater.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment responseTime frame: From the start of study treatment (Day 1) up to the end of week 4, week 8 and week 12.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

    Tianjin, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.